TRT and semaglutide stacking: what the science actually says

What did @ayub_ace actually say?

He made a specific and testable claim: after years of anabolic steroid use, his lipid panel finally came back within range, and he credits retatrutide plus TRT for the change. In his words, "my lipid profile has changed drastically" and his LDL dropped while HDL rose. He was also honest about something most influencers skip: he spent years doing blast-and-cruise cycles and even with standard lipid-support supplements like omega-3s, citrus bergamot, and ubiquinol, he never achieved clean bloodwork until now. That kind of transparency is actually useful. What he did not do was share actual numbers, timelines, or a controlled comparison. One person's before-and-after bloods are not a clinical trial.

Does the science back this up?

There is real mechanistic support for why retatrutide could improve lipid profiles, but the evidence is early and the picture is more complicated than the video suggests.

Retatrutide is a triple agonist hitting GIP, GLP-1, and glucagon receptors. The GLP-1 component alone has a documented track record here. A 2023 trial by Ludvik et al. in The Lancet showed semaglutide reduced LDL cholesterol and triglycerides in patients with type 2 diabetes, and the SELECT trial (Lincoff et al., 2023, NEJM) found cardiovascular risk reduction with semaglutide independent of weight loss. Retatrutide itself was studied by Jastreboff et al. in 2023 in NEJM, showing significant weight reduction and improvements in metabolic markers including triglycerides and HDL in the phase 2 cohort. The glucagon receptor component adds a hepatic fat-clearing effect that could specifically help someone with steroid-induced dyslipidemia, since anabolics impair hepatic lipase activity and suppress HDL synthesis directly. So the biology is plausible. But none of these trials enrolled people actively on anabolic steroids or TRT supraphysiologic doses.

What did they get wrong (or right)?

He got the direction of the effect right: GLP-1 class drugs do appear to improve lipid profiles, and the combination of weight loss plus direct metabolic effects on the liver is a credible mechanism. Credit where it is due.

What he got wrong, or at least incomplete, is the attribution. He is also on TRT, which if dosed correctly to bring testosterone into physiological range can itself partially reverse the HDL suppression caused by supraphysiologic androgens. Stopping blast cycles entirely would independently improve lipid markers in most people. He also used citrus bergamot and omega-3s for years, which have their own modest LDL-lowering effects. You cannot isolate retatrutide as the active ingredient in a stack of four or five interventions without a controlled comparison. The claim that retatrutide "changed the game" is not wrong, but it is overconfident given the variables at play. This is a correlation story told as a causation story.

What should you actually know?

A few things that did not make it into the video.

• Anabolic androgenic steroids reliably tank HDL. A 2019 meta-analysis by Baggish et al. in Circulation found AAS users had significantly lower HDL and higher LDL compared to non-users, with effects persisting long after cessation in long-term users.
• GLP-1 receptor agonists reduce cardiovascular events in high-risk populations, but these trials did not include AAS users as a study group. Extrapolating SELECT trial data to bodybuilders is reasonable biologically but not proven.
• Retatrutide is still in phase 3 trials. Long-term safety data, especially for people layering it on top of exogenous androgens, does not exist yet.
• If you are on TRT and your lipid panel is a mess, the first conversation should be with a physician who specializes in men's health and endocrinology, not a TikTok comment section.
• Compounded retatrutide is not the same product used in the Jastreboff 2023 trial. Purity, dosing accuracy, and bioavailability of compounded peptides vary by pharmacy.